Advertisement
Finance
Subscribe to Finance

The Lead

Economic Burden of Diabetes on the Rise; Hookah Smoke Warning

November 21, 2014 8:23 am | Videos | Comments

New research finds that the costs of diabetes care and lost productivity due to the condition totaled $322 billion in 2012. Also, new warnings about hookah smoke.               

German Court: e-Cigarette Liquids Not Medicines

November 20, 2014 3:32 pm | News | Comments

A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal...

Surviving Pharma’s Uncertain Future

November 20, 2014 10:08 am | by Nathan Furr and Jeff Dyer | Articles | Comments

The average cost of developing an approved therapy is around $4.3 billion dollars for companies...

Cystic Fibrosis Foundation Sells $3.3B in Vertex Drug Royalties

November 20, 2014 8:48 am | News | Comments

The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs...

View Sample

FREE Email Newsletter

Soaring Generic Drug Prices Draw Senate Scrutiny

November 20, 2014 8:35 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.     

McKinsey Report Says Obesity Costs Hit $2T

November 20, 2014 8:19 am | News | Comments

A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.        

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

November 20, 2014 8:00 am | News | Comments

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.

Advertisement

Shire to Relocate Over 500 Jobs to Massachusetts

November 19, 2014 2:04 pm | News | Comments

Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachusetts as the company's U.S. operational headquarters. The transition is a continuation of the company's 'One Shire' efficiency program and will streamline business globally through two principal locations - Massachusetts and Switzerland.

Despite Patent Cliffs, Pharmaceutical Market Shows Signs of Stability, says GlobalData

November 19, 2014 11:52 am | News | Comments

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData.  

Cost to Develop and Win Marketing Approval for a New Drug Is $2.6B

November 19, 2014 8:41 am | News | Comments

Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development.    

Knight Sells Priority Review Voucher to Gilead

November 19, 2014 8:15 am | News | Comments

Knight Therapeutics today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV"). Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV.        

GlobalData Director: Actavis Continues Consolidation March with Highly Priced Allergan Deal

November 18, 2014 8:21 am | News | Comments

According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The integration of Allergan and Forest will help grow Actavis to a $22 billion healthcare company in 2015. This is a dramatic elevation from its $8.7 billion revenues recorded in 2013, the year in which Actavis completed the $5 billion acquisition of Warner Chilcott."

Advertisement

Zoetis Authorizes $500 Million Share Repurchase Program

November 18, 2014 8:02 am | News | Comments

Zoetis today announced that its Board of Directors has authorized a $500 million share repurchase program as part of its capital allocation plans. The shares are expected to be repurchased at the discretion of management, depending on market conditions and business needs.

The "Vaccine Court" Keeps Claimants Waiting

November 17, 2014 3:59 pm | by MITCH WEISS, Associated Press; JUSTIN PRITCHARD, Associated Press; TROY THIBODEAUX, Associated Press | News | Comments

To help people harmed by shots, Congress created the National Vaccine Injury Compensation Program. Government doctors and lawyers review claims. If they believe it is more likely than not that a vaccine — and not something else — caused the injury, they tap a $3.5 billion fund to pay for future care and lost wages. That fund is replenished by a 75-cent tax on each vaccine.

Actavis to Spend $66B on Allergan

November 17, 2014 10:24 am | by TOM MURPHY, AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.             

Zoetis to Purchase Assets of Abbott Animal Health

November 17, 2014 8:35 am | News | Comments

Zoetis today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite.      

World Bank: Ebola Fund Would Create Incentives

November 17, 2014 8:28 am | by ROD McGUIRK, Associated Press | News | Comments

A proposed global emergency fund to contain the next Ebola outbreak would also provide an incentive for drug companies to develop vaccines to fight other future pandemics, World Bank President Jim Yong Kim said Friday.      

Advertisement

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.

Zoetis Adopts Shareholder Rights Plan

November 14, 2014 6:11 pm | by The Associated Press | News | Comments

Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.

Geron Could Get $935M in Blood Disorder Drug Deal

November 13, 2014 5:12 pm | by The Associated Press | News | Comments

Geron Corp. could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson. Geron said Janssen Biotech agreed to pay it $35 million upfront.        

Ackman Takes Stake in Animal-Health Company Zoetis

November 13, 2014 12:09 pm | Videos | Comments

Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.               

Golden Gate Capital Acquires ANGUS Chemical Company

November 12, 2014 3:12 pm | News | Comments

Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.              

Dallas Hospital Reaches Deal with Ebola Victim's Family

November 12, 2014 9:09 am | Videos | Comments

The family of Ebola victim Thomas Eric Duncan has reached a settlement with Dallas Presbyterian Hospital. Also, the last remaining Ebola patient in the U.S., Dr. Craig Spencer, was released from the hospital.       

Intarcia and Servier Sign $1B Diabetes Partnership Deal

November 12, 2014 8:46 am | News | Comments

Intarcia Therapeutics has announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650, Intarcia's phase 3 investigational therapy for the treatment of type 2 diabetes.

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.

Zoetis Shares Jump on Activist's Investment

November 11, 2014 5:40 pm | by The Associated Press | News | Comments

Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale. The company said that it did receive a call from Ackman indicating that the firm has made an investment in Zoetis.

GlobalData Analyst: Biologics to Complement Statins in Cholesterol Treatment Space

November 11, 2014 7:56 am | News | Comments

Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData.

Orexigen Rises as Weight Loss Drug Review Proceeds

November 10, 2014 2:24 pm | News | Comments

Shares of Orexigen Therapeutics jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.         

Skin Cancer Treatment Becoming More Expensive; Obesity Research

November 10, 2014 8:59 am | Videos | Comments

A new study shows that the cost for treating skin cancer has increased by 126 percent in recent years. Also, new research on obesity in children.                  

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading